Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Industrie
Biotecnologia
Settore
Assistenza sanitaria
Identificatore
ISIN
AU000000IMM6
Ticker primario
IMM
Knockouts
<contenitore>Dati LSX</contenitore> · Dati finanziari di FactSet
